+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019

  • ID: 4894228
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1301 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 4SC AG
  • BioIntegrator Ltd
  • Eternity Bioscience Inc
  • ImmuneTarget Inc
  • MingSight Pharmaceuticals
  • Pharmapraxis
  • MORE
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 53, 65, 2, 6, 62, 7 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 9, 15 and 5 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4SC AG
  • BioIntegrator Ltd
  • Eternity Bioscience Inc
  • ImmuneTarget Inc
  • MingSight Pharmaceuticals
  • Pharmapraxis
  • MORE
Introduction
Chronic Lymphocytic Leukemia (CLL) - Overview
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Companies, H2 2019 (Contd..16), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Adicet Bio Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AI Therapeutics, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor Bioscience LLC, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Anew Oncology Inc, H2 2019

List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • ABL Bio Inc
  • ACEA Therapeutics Inc
  • Acerta Pharma BV
  • ADC Therapeutics SA
  • Adicet Bio Inc
  • Adlai Nortye Biopharma Co Ltd
  • Aeglea BioTherapeutics Inc
  • AI Therapeutics
  • Altor Bioscience LLC
  • Anew Oncology Inc
  • Apotex Inc
  • Ascenta Therapeutics Inc
  • Ascentage Pharma Group International
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bantam Pharmaceutical LLC
  • Bayer AG
  • BeiGene Ltd
  • Beijing GD Initiative Cell Therapy Technology Co Ltd
  • Beijing Immunochina Medical Science & Technology Co Ltd
  • Beijing Mabworks Biotech Co Ltd
  • Bellicum Pharmaceuticals Inc
  • BendaRx Corp
  • Bio-Path Holdings Inc
  • BioIntegrator Ltd
  • Bionomics Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • CARsgen Therapeutics Ltd
  • CASI Pharmaceuticals Inc
  • Catapult Therapeutics BV
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Celltrion Inc
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Centaurus Biopharma Co Ltd
  • CrystalGenomics Inc
  • Cyclacel Pharmaceuticals Inc
  • Cyteir Therapeutics Inc
  • Deciphera Pharmaceuticals Inc
  • Dizal (Jiangsu) Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Ergon Pharmaceuticals LLC
  • Eternity Bioscience Inc
  • Eureka Therapeutics Inc
  • Exinda Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • GammaDelta Therapeutics Ltd
  • GeneaMed Ltd
  • Genentech Inc
  • Generium
  • Gilead Sciences Inc
  • GLG Pharma SA
  • Grid Therapeutics LLC
  • Grupo Ferrer Internacional SA
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • Hangzhou Hezheng Pharmaceutical Co Ltd
  • Hangzhou Minsheng Pharmaceutical Group Co Ltd
  • Heidelberg Pharma AG
  • Helocyte Biosciences Inc
  • Hengenix Biotech Inc
  • HRAIN Biotechnology Co Ltd
  • Hutchison MediPharma Ltd
  • Hybrigenics SA
  • iBio Inc
  • IGM Biosciences Inc
  • Immatics Biotechnologies GmbH
  • ImmuneTarget Inc
  • Immunomedics Inc
  • Incuron LLC
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innate Pharma SA
  • InnoCare Pharma Ltd
  • Innovative Cellular Therapeutics Co Ltd
  • Invectys SA
  • IO Biotech ApS
  • Iovance Biotherapeutics Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kancera AB
  • Karyopharm Therapeutics Inc
  • Kecellitics Biotech Co Ltd
  • LegoChem Biosciences Inc
  • LFB SA
  • MEI Pharma Inc
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • MingSight Pharmaceuticals
  • Miragen Therapeutics Inc
  • MorphoSys AG
  • Mustang Bio Inc
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Neon Therapeutics Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nordic Nanovector ASA
  • NovalGen Ltd
  • Novartis AG
  • Nurix Inc
  • OncoTartis Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Orano Med LLC
  • Panorama Research Inc
  • PEP-Therapy SAS
  • PersonGen Biomedicine Suzhou Co Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Pharmapraxis
  • PIQUR Therapeutics AG
  • Plexxikon Inc
  • Precision Biosciences Inc
  • Promethera Biosciences SA
  • Qurient Co Ltd
  • Revitope Oncology Inc
  • Rhizen Pharmaceuticals SA
  • Sanofi
  • SFA Therapeutics LLC
  • Shanghai GeneChem Co Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Sian Wuhan Medical Technology Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • SpecificiT Pharma Inc
  • Supratek Pharma Inc
  • Surface Oncology Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TG Therapeutics Inc
  • Tolero Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • United BioPharma Inc
  • VelosBio Inc
  • Verastem Inc
  • Viralytics Pty Ltd
  • Wuhan Bio-Raid Biotechnology Co Ltd
  • XEME BioPharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll